The idiopathic intracranial hypertension treatment trial: Design considerations and methods

Journal of Neuro-Ophthalmology

Volumn 34, Issue 2, 2014, Pages 107-117

  Friedman, Deborah I ^a   McDermott, Michael P ^d   Kieburtz, Karl ^c   Kupersmith, Mark ^h   Stoutenburg, Ann ^c   Keltner, John L ^g   Feldon, Steven E ^b   Schron, Eleanor ^f   Corbett, James J ⁱ   Wall, Michael ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Departments of Ophthalmology   (United States)

^c Center for Human Experimental Therapeutics Department of Biostatistics and Computational Biology   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f NATIONAL EYE INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; PLACEBO; RETINOL; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DRUG TREATMENT FAILURE; FOLLOW UP; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; IDIOPATHIC INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; METHODOLOGY; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PAPILLEDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA EDEMA; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY DESIGN; VISUAL ACUITY; VISUAL FIELD DEFECT; VITAMIN METABOLISM; ADOLESCENT; ADULT; CEREBROSPINAL FLUID PRESSURE; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EYE FUNDUS; FEMALE; MALE; MIDDLE AGED; PERCEPTUAL DISORDERS; PERIMETRY; PSEUDOTUMOR CEREBRI; RETROSPECTIVE STUDY; VISUAL FIELD; YOUNG ADULT;

ACETAZOLAMIDE; ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CEREBROSPINAL FLUID PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; MALE; MIDDLE AGED; PERCEPTUAL DISORDERS; PSEUDOTUMOR CEREBRI; RESEARCH DESIGN; RETROSPECTIVE STUDIES; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84900823890     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0000000000000114     Document Type: Article

References (54)

1. Wall M. Idiopathic intracranial hypertension. Neurol Clin. 1991;9:73-95.
2. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988;45:875-877.
3. Garrett JH, Corbett JJ, Braswell R. The incidence of idiopathic intracranial hypertension in Mississippi. Paper presented at: The North American Neuro-ophthalmology Society; 2004; Orlando, FL.
4. Wall MW, George D. Idiopathic intracranial hypertension (pseudotumor cerebri). A prospective study of 50 patients. Brain. 1991;114:155-180.
5. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2005;CD003434.
6. Smith JL. Whence pseudotumor cerebri? J Clin Neuroophthalmol. 1985;5:55-56.
7. Wall M, White WN. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci. 1998;39:134-142.
8. Kleinschmidt JJ, Digre KB, Hanover R. Idiopathic intracranial hypertension: relationship to depression, anxiety and quality of life. Neurology. 2000;54:319-324.
9. Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, Biousse V, Lee AG, Wall M, Kardon R, Acierno MD, Corbett JJ, Maguire MG, Balcer LJ. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007;143:635-641.
10. Kammerdiener L, Friedman DI. Patient interviews and focus groups to determine outcome measures for idiopathic intracranial hypertension. Paper presented at: North American Neuro-ophthalmology Society; 2010; Tucson, AZ.
11. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
12. Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlf CG, Dowson A, Tepper S. A sixitem short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963-974.
13. Cleary PA, Beck RW, Anderson MM Jr, Kenny DJ, Backlund JY, Gilbert PR. Design, methods and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials. 1993;14:123-142.
14. Frisn L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry. 1982;45:13-18.
15. McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on CSF production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther. 1974;189:194-200.
16. Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, ed. Neuro-ophthalmology. Symposium of the University of Miami and the Bascom Palmer Eye Institute. Vol IX. Saint Louis, MO: The C.V. Mosby Company; 1977:199-206.
17. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg. 1978;49:256-263.
18. Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalamol. 1988;8:93-98.
19. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977;95:1378-1382.
20. Kupersmith MJ, Gamell L, Turbin R, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998;50:1094-1098.
21. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension. Ophthalmology. 1998;105:2313-2317.
22. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med. 1974;133:802-807.
23. Jeffery RW, Sherwood NE, Brelje K, Pronk NP, Boyle R, Boucher JL, Hase K. Mail and phone interventions for weight loss in a managed-care setting: weigh-to-be one-year outcomes. Int J Obes Relat Metab Disord. 2003;27:1584-1592.
24. Sherwood NE, Jeffery RW, Pronk NP, Boucher JL, Hanson A, Boyle R, Brelje K, Hase K, Chen V. Mail and phone interventions for weight loss in a managed-care setting: weighto-be 2-year outcomes. Int J Obes (Lond). 2006;30:1565-1573.
25. Brownell KD. LEARN Program for Weight Management, 10th edition. Euless, TX: American Health Publishing Company, 2000.
26. Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990;51:241-247.
27. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27:537-549.
28. Friedman DI, Streeten DHP. Idiopathic intracranial hypertension and orthostatic edema may share a common pathogenesis. Neurology. 1998;50:1099-1104.
29. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. American Heart Association Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47: 296-308.
30. National Cholesterol Education Program. The report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). Circulation. 2002;106:3143-3421.
31. Ledikwe JH, Blanck HM, Khan LK, Serdula MK, Seymour JD, Tohill BC, Rolls BJ. Low-energy-density diets are associated with high diet quality in adults in the United States. J Am Diet Assoc. 2006;106:1172-1180.
32. Wansink B, Chandon P. Meal size, not body size, explains errors in estimating the calorie content of meals. Ann Intern Med. 2006;145:326-332.
33. Wansink B. Environmental factors that increase the food intake and consumption volume of unknowing consumers. Annu Rev Nutr. 2004;24:455-479.
34. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996;52:1324-1333.
35. Schafer JL. Analysis of Incomplete Multivariate Data. Boca Raton, FL: Chapman and Hall/CRC, 1997.
36. Li KH. Imputation using Markov chains. J Statist Comput Simul. 1988;30:57-79.
37. Liu C. Bartletts decomposition of the posterior distribution of the covariance for normal monotone ignorable missing data. J Mult Anal. 1993;46:198-206.
38. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, Carroll RJ. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5:445-464.
39. Buchheit W, Burton C, Haag B, Shaw D. Papilledema and idiopathic intracranial hypertension. Report of familial occurrence. N Engl J Med. 1969;280:938-942.
40. Coffey CE, Ross DR, Massey EW, Olanow CW. Familial benign intracranial hypertension and depression. Can J Neurol Sci. 1982;9:45-47.
41. Gardner K, Cox T, Digre KB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review. Neurology. 1995;45:6-10.
42. Howe J, Saunders M, Clarke P. Familial benign intracranial hypertension. Acta Neurochir (Wien). 1973;29:173-175.
43. Kharode C, McAbee G, Sherman J, Kaufman M. Familial intracranial hypertension: report of a case and review of the literature. J Child Neurol. 1992;7:196-198.
44. Traviesa DC, Schwartzman RJ, Glaser JS, Savino P. Familial benign intracranial hypertension. J Neurol Neurosurg Psychiatry. 1976;39:420-423.
45. Lombaert A, Carton H. Benign intracranial hypertension due to A-hypervitaminosis in adults and adolescents. Eur Neurol. 1976;14:340-350.
46. Marie J, See G. Acute hypervitaminosis A of the infant. Its clinical manifestation with benign acute hydrocephaly and pronounced bulge of the fontanel. A clinical and biologic study. AMA Am J Dis Child. 1954;73:731-736.
47. Gerber A, Raab AR. Vitamin A poisoning in adults. With description of a case. Am J Med. 1954;16:729-745.
48. Jacobson DM, Berg R, Wall M, Digre KB, Corbett JJ, Ellefson RD. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology. 1999;53:1114-1118.
49. Selhorst JB, Kulkantrakorn K, Corbett JJ, Leira EC, Chung SM. Retinol-binding protein in idiopathic intracranial hypertension. J Neuroophthalmol. 2000;20:250-252.
50. Warner JEA, Bernstein PS, Yemelyanov A, Alder SC, Farnsworth ST, Digre KB. Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. Ann Neurol. 2002;52:647-650.
51. International HapMap Consortium. The International HapMap Project. Nature. 2003;426:780-796.
52. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ, Weber RJ, Haussler D, Kent WJ. The UCSC Genome Browser database. Nucleic Acids Res. 2003;31:51-54.
53. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-311.
54. Blaner WS. Radioimmunoassays for retinol-binding protein, cellular retinol-binding protein, and cellular retinoic acid-binding protein. Methods Enzymol. 1990;189:270-281